{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:31:37Z","timestamp":1767918697824,"version":"3.49.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Activated phosphoinositide 3-kinase-<jats:italic>\u03b4<\/jats:italic> syndrome 1 (APDS1) is a combined immunodeficiency caused by a heterozygous gain-of-function mutation in <jats:italic>PIK3CD<\/jats:italic>, encoding the p110<jats:italic>\u03b4<\/jats:italic> catalytic subunit of phosphoinositide 3-kinase <jats:italic>\u03b4<\/jats:italic> (PI3K<jats:italic>\u03b4<\/jats:italic>). APDS1 is characterized by recurrent sinopulmonary infections, leading to airway damage, chronic herpes viremia, lymphoproliferation, and autoimmune and inflammatory diseases. Several cases of systemic lupus erythematosus (SLE) have been reported in APDS1; however, Sj\u00f6gren's syndrome (SS) or an SS-like phenotype is rarely described in patients with APDS1. In this study, we report a 4-year-old girl with APDS1 who did not experience recurrent sinopulmonary infections and chronic viremia but presented with cytopenia, proteinuria, hypocomplementemia, and positive antinuclear antibodies that met the classification criteria for SLE. Additionally, the patient also mimicked a secondary SS-like phenotype based on recurrent parotitis and labial salivary gland biopsy. The patient achieved remission after treatment with sirolimus and immunosuppressive therapy. This case report enriches the clinical phenotype of APDS1 and provides a reference for the diagnosis and therapy of patients with APDS1.<\/jats:p>","DOI":"10.3389\/fped.2022.1077324","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T07:02:43Z","timestamp":1671519763000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Activated PI3K\u03b4 syndrome 1 mimicking systemic lupus erythematosus and secondary Sj\u00f6gren's syndrome-like phenotype without recurrent infections: A case report"],"prefix":"10.3389","volume":"10","author":[{"given":"Jing","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jijun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyue","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/315239a0","article-title":"Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation","volume":"315","author":"Whitman","year":"1985","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1172\/JCI77198","article-title":"Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling","volume":"124","author":"Walsh","year":"2014","journal-title":"J Clin Invest"},{"key":"B3","doi-asserted-by":"publisher","first-page":"iii70","DOI":"10.1136\/ard.2008.098459","article-title":"The PI3K\/Akt\/mTOR pathway in innate immune cells: emerging therapeutic applications","volume":"67","author":"Weichhart","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B4","first-page":"69","article-title":"PI3K\/Akt signaling in peripheral T lymphocytes from systemic lupus erythematosus patients","volume":"68","author":"Besliu","year":"2009","journal-title":"Roum Arch Microbiol Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/82_2010_45","article-title":"PI3Ks In lymphocyte signaling and development","volume":"346","author":"Okkenhaug","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.1243292","article-title":"Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage","volume":"342","author":"Angulo","year":"2013","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e15329","DOI":"10.1097\/MD.0000000000015329","article-title":"A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: a case report","volume":"98","author":"Li","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri.2016.93","article-title":"PI3Kdelta and primary immunodeficiencies","volume":"16","author":"Lucas","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s10875-014-0012-9","article-title":"Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility","volume":"34","author":"Crank","year":"2014","journal-title":"J Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fimmu.2018.00543","article-title":"Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase delta syndrome: the European society for immunodeficiencies-activated phosphoinositide 3-kinase delta syndrome registry","volume":"9","author":"Maccari","year":"2018","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"652405","DOI":"10.3389\/fped.2021.652405","article-title":"Activated PI3kinase delta syndrome\u2014a multifaceted disease","volume":"9","author":"Thouenon","year":"2021","journal-title":"Front Pediatr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1182\/blood.2019002072","article-title":"Increased activation of PI3 kinase-delta predisposes to B-cell lymphoma","volume":"135","author":"Durandy","year":"2020","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191336","article-title":"Activated PI3Kdelta breaches multiple B cell tolerance checkpoints and causes autoantibody production","volume":"217","author":"Lau","year":"2020","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.gendis.2020.04.012","article-title":"Phenotypic characterization of patients with activated PI3Kdelta syndrome 1 presenting with features of systemic lupus erythematosus","volume":"8","author":"Wang","year":"2021","journal-title":"Genes Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"702546","DOI":"10.3389\/fped.2021.702546","article-title":"Case report: Hodgkin lymphoma and refractory systemic lupus erythematosus unveil activated phosphoinositide 3-kinase-delta syndrome 2 in an adult patient","volume":"9","author":"Conti","year":"2021","journal-title":"Front Pediatr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/acr.23839","article-title":"Juvenile Sjogren's syndrome: clinical characteristics with focus on salivary gland ultrasonography","volume":"72","author":"Hammenfors","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.55563\/clinexprheumatol\/volsh1","article-title":"Hypergammaglobulinaemia predicts glandular and extra-glandular damage in primary Sjogren's syndrome: results from the KISS cohort study","volume":"39","author":"Koh","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10875-005-4091-5","article-title":"Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome","volume":"25","author":"Jonsson","year":"2005","journal-title":"J Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \u201cactivated PI3Kdelta syndrome\u201d-targeted therapy with the PI3Kdelta inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3389\/fimmu.2018.02043","article-title":"The treatment of activated PI3Kdelta syndrome","volume":"9","author":"Coulter","year":"2018","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jaci.2021.04.036","article-title":"International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome","volume":"149","author":"Dimitrova","year":"2022","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1077324\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T07:02:45Z","timestamp":1671519765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1077324\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":24,"alternative-id":["10.3389\/fped.2022.1077324"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.1077324","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"article-number":"1077324"}}